Related Experiment Videos

Pharmacokinetic study of valproic acid in a neonate

Pediatric Pharmacology (New York, N.Y.)
|January 1, 1982
PubMed

Insights

Valproic acid pharmacokinetics in neonates show a prolonged half-life (t 1/2) that matures with age. Clearance (Cl) and half-life (t 1/2) in infants change significantly by 6 months, indicating developmental changes.

Area of Science:

  • Pharmacology
  • Pediatric Medicine
  • Drug Metabolism

Background:

  • Valproic acid is a widely used anticonvulsant medication.
  • Understanding its pharmacokinetic profile in neonates and infants is crucial for safe and effective dosing.

Observation:

  • A single neonate (39 weeks gestational age) received valproic acid at 24 days postpartum (7.5 mg/kg) and again at 6 months (13.5 mg/kg/day).
  • Serum samples were collected over 24 hours at 24 days and 12 hours at 6 months.
  • Pharmacokinetic parameters were calculated using a one-compartment model.

Findings:

  • At 24 days postpartum, valproic acid exhibited a half-life (t 1/2) of 17.2 hours, clearance (Cl) of 0.18 ml/min/kg, and volume of distribution (Vd) of 0.28 liter/kg.
  • By 6 months of age, clearance (Cl) increased to 0.53 ml/min/kg, half-life (t 1/2) decreased to 7.5 hours, and Vd remained similar (0.34 liter/kg).
  • The neonate's half-life was shorter than in younger neonates but longer than in adults.

Implications:

  • Hepatic enzyme maturation and co-administration of other anticonvulsant drugs likely contribute to the observed changes in valproic acid pharmacokinetics.
  • These findings highlight the importance of age-specific dosing adjustments for valproic acid in pediatric populations.
  • Further research is warranted to elucidate the precise mechanisms driving these pharmacokinetic alterations.

Related Concept Videos